Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.33 |
| ▸ | ADA | P00813 | 2/20 | 0.33 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884029 | 0.95 | NOS2 (0.42) | NOS2NOS3TLR8ADA | |
| SCHEMBL20621321 | 0.83 | NOS2 (0.48) | NOS2NOS3LMNA | |
| SCHEMBL22096911 | 0.79 | L3MBTL1 (0.34) | TLR8ADALMNA | |
| SCHEMBL24576064 | 0.77 | NOS3 (0.37) | NOS2NOS3TLR8BDKRB2 | |
| SCHEMBL20267199 | 0.76 | NOS3 (0.36) | NOS2NOS3LMNA | |
| SCHEMBL19779562 | 0.75 | NOS2 (0.44) | NOS2NOS3LMNA | |
| SCHEMBL19590668 | 0.75 | NOS2 (0.56) | NOS2NOS3LMNA | |
| SCHEMBL23491192 | 0.75 | L3MBTL1 (0.36) | ADA | |
| Methylamine SCHEMBL23201523 | 0.73 | NOS2 (0.54) | NOS2NOS3LMNA | |
| SCHEMBL20621277 | 0.72 | NOS2 (0.33) | NOS2NOS3TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | NOS2 1227/4885NOS3 887/4885TLR8 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.